Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: Clinical, histological, and molecular follow-up

Leukemia and Lymphoma

Volumn 51, Issue 2, 2010, Pages 284-290

  Lévy, Michaël ^a   Copie Bergman, Christiane ^a,b,c   Molinier Frenkel, Valérie ^a,b,c   Riou, Audrey ^a   Haioun, Corinne ^a,c   Gaulard, Philippe ^a,b,c   Delfau Larue, Marie Héléne ^a,b,c   Sobhani, Iradj ^a,c   Leroy, Karen ^a,b,c   Delchier, Jean Charles ^a,c  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

^c FACULTÉ DE MÉDECINE   (France)

Author keywords

Chlorambucil; MALT; Rituximab; T(11; 18)

Indexed keywords

CHLORAMBUCIL; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 18; CLINICAL ARTICLE; CLINICAL EXAMINATION; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROSCOPY; HISTOPATHOLOGY; HUMAN; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 18; FEMALE; FOLLOW-UP STUDIES; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 76349100971     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903431820     Document Type: Article

References (31)

1. Ye H, Liu H, Attygalle A, et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood 2003;102:1012-1018.
2. Streubel B, Simonitsch-Klupp I, Müllauer L, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 2004; 18:1722-1726.
3. Inagaki H, Nakamura T, Li C, et al. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol 2004;28:1560-1567.
4. Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa- associated lymphoid tissue lymphomas. Blood 1999;93:3601-3609.
5. Liu H, Ye H, Ruskone-Fourmestraux A, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002;122: 1286-1294.
6. Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol 2007;136:521-538.
7. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003;21:4157-4164.
8. Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995;13:2524-2529.
9. Lévy M, Copie-Bergman C, Traulle C, et al. Conservative treatment of primary gastric low grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. Am J Gastroenterol 2002;97:292-297.
10. Lévy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoural response of lowgrade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 2005;23: 5061-5066.
11. Raderer M, Jager G, Brugger S, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 2003;65:306-310.
12. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741-2745.
13. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non Hodgkin's lymphoma resistant to or non eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979-1983.
14. Musshoff K. Klinische stadieneinteilung der nicht-Hodgkin lymphome. Strahlentherapie 1977;153:218-221.
15. Lévy M, Hammel P, Lamarque D, et al. Endoscopic ultrasonography for the initial staging and follow-up in patients with low-grade gastric lymphoma of mucosa-associated lymphoid tissue treated medically. Gastrointest Endosc 1997;46:328-333.
16. Martinelli G, Laszlo D, Bertolini F, et al. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. Br J Haematol 2003;123:271-277.
17. Isaacson PG, Wright DH. Malignant lymphoma of mucosaassociated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983;52:1410-1416.
18. Tankovic J, Chaumette-Planckaert MT, Deforges L et al. Routine use of real-time PCR for detection of Helicobcater pylori and of clarithromycine resistance mutations. Gastroenterol Clin Biol 2007;31:792-795.
19. Copie-Bergman C, Gaulard P, Lavergne-Slove A, et al. Proposal for a new histological grading system for post-treatment evaluation of gastricMALT lymphoma. Gut 2003; 52:1656.
20. Zompi S, Couderc LJ, Cadranel J, et al. Clonality analysis of alveolar B lymphocytes contributes to the diagnostic strategy in clinical suspicion of pulmonary lymphoma. Blood 2004; 103:3208-3215.
21. Streubel B, Ye H, Du MQ, et al. Translocation t(11 18)(q21 q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology 2004;66: 476-480.
22. Zinzani PL, Stefoni V, Musuraca G, et al. Fludarabinecontaining chemotherapy as frontline treatment of non gastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 2004;100:2190-2194.
23. Bertoni F, Conconi A, Capella C, et al. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood 2002;99: 2541-2544.
24. Thiede C, Wündisch T, Alpen B, et al. Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol 2001; 19:1600-1609.
25. de Mascarel A, Ruskone-Fourmestraux A, Lavergne-Slove A, Megraud F, Dubus P, Merlio JP Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue. Virchows Arch 2005;446:219-224.
26. Wündisch T, Thiede C, Morgner A, et al. Long-term followup of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005;23:8018-8024.
27. Montalban C, Santon A, Redondo C, et al. Long-term persistence of molecular disease after histological remission in low-grade gastric MALT lymphoma treated with H. pylori eradication. Lack of association with translocation t(11;18): a 10-year updated follow-up of a prospective study. Ann Oncol 2005;16:1539-1544.
28. Salar A, Bellosillo B, Serrano S, Besses C. Persistent residual disease in t(11;18)(q21 q21) positive gastric mucosaassociated lymphoid tissue lymphoma treated with chemotherapy or rituximab. J Clin Oncol 2005;23:7361-7362.
29. Santón A, García-Cosio M, Bellosillo B, et al. Persistent monoclonality after histological remission in gastric mucosaassociated lymphoid tissue lymphoma treated with chemotherapy and/or surgery: influence of t(11;18)(q21;q21). Leuk Lymphoma 2008;49:1516-1522.
30. Raderer M, Streubel B, Woehrer S, et al. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res 2005;11:3349-3352.
31. Copie-Bergman C, Locher C, Lévy M, et al. Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma? Ann Oncol 2005;16:1232-1236.